Pub Date : 2023-02-21DOI: 10.1007/s44178-023-00025-0
Yurong Jiao, Xiaoxia Zhou, Yao Ye, Q. Xiao, Xiangxing Kong, K. Ding, Jun Li
{"title":"Short-term outcomes following purse-string versus conventional closure of ileostomy wounds in Chinese colorectal cancer patients — a single center retrospective study","authors":"Yurong Jiao, Xiaoxia Zhou, Yao Ye, Q. Xiao, Xiangxing Kong, K. Ding, Jun Li","doi":"10.1007/s44178-023-00025-0","DOIUrl":"https://doi.org/10.1007/s44178-023-00025-0","url":null,"abstract":"","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42287241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01Epub Date: 2023-06-07DOI: 10.1007/s44178-023-00041-0
Sharon S Poh, Boon Fei Tan, Fang Yue Yong, Kam Weng Fong, Joseph T S Wee, Terence W K Tan, Melvin L K Chua, Kiattisa Sommat, Fu Qiang Wang, Yoke Lim Soong
Purpose or objective: The COVID-19 pandemic has resulted in significant healthcare implications, with care for cancer patients compromised due to resource diversion towards battling the pandemic. We aim to investigate the impact of the peak wave of the pandemic in 2020 on the delivery of cancer care in Singapore, specifically via our nasopharyngeal carcinoma (NPC) treatment data. This study applies real world numbers to the impact of COVID-19 on cancer care delivery in Singapore. The choice of nasopharyngeal cancer allows a good direct estimate of common treatment measures such as time to biopsy, time to staging scans, time to treatment commencement, due to its clear protocol and algorithms for staging and treatment; thus serving as an excellent surrogate for the effectiveness and timeliness of the different aspects of cancer care delivery.
Materials and methods: In this retrospective study, we included all patients with newly diagnosed NPC from 1st January to 31st May from 2017 to 2020 at our centre. This time period was chosen as it coincided with the period in 2020 during the COVID-19 pandemic where there was the most strain on healthcare resources and the most restrictions on population movement within Singapore, which may impact on healthcare seeking behaviour. Narrowing down the time period to the first 5 months of the 4 respective years also allowed us to reduce the effect of annual seasonal variation in patient numbers seen as a result of holidays and festive periods such as the Lunar New Year and scheduled school holidays. Electronic medical records (EMR) were accessed. Only newly diagnosed NPC cases were included in our analysis. Patients with second synchronous primary malignancies or NPC disease recurrence were excluded. Data analysis was carried out using a combination of SPSS and Microsoft Excel.
Results: Significantly, there was a reduction of 37-46.3% in newly diagnosed NPC cases during the peak of the COVID-19 pandemic from January to end May 2020 compared to the preceding three years. Despite the reduction in numbers of newly diagnosed NPC, there was no statistically significant differences in delay from biopsy to the first radiation oncology visit and from biopsy to the first day of treatment in 2020 compared to the preceding years. All the patients treated in our centre also received the standard NPC treatment for their disease stage as per international guidelines.
Conclusion: We recommend a heightened awareness of the dangers of delaying cancer presentation and care in healthcare policies and resource allocation and at the same time, encourage patient's confidence in their ability to seek care. With the resurgence of new COVID-19 variants and case numbers worldwide and in Singapore, this study focuses upon the need to be aware of the exigencies of other clinical groups in resource utilization. It would be instructive to compare this stud
{"title":"The impact of the COVID-19 pandemic on nasopharyngeal carcinoma patients - a national cancer centre experience.","authors":"Sharon S Poh, Boon Fei Tan, Fang Yue Yong, Kam Weng Fong, Joseph T S Wee, Terence W K Tan, Melvin L K Chua, Kiattisa Sommat, Fu Qiang Wang, Yoke Lim Soong","doi":"10.1007/s44178-023-00041-0","DOIUrl":"10.1007/s44178-023-00041-0","url":null,"abstract":"<p><strong>Purpose or objective: </strong>The COVID-19 pandemic has resulted in significant healthcare implications, with care for cancer patients compromised due to resource diversion towards battling the pandemic. We aim to investigate the impact of the peak wave of the pandemic in 2020 on the delivery of cancer care in Singapore, specifically via our nasopharyngeal carcinoma (NPC) treatment data. This study applies real world numbers to the impact of COVID-19 on cancer care delivery in Singapore. The choice of nasopharyngeal cancer allows a good direct estimate of common treatment measures such as time to biopsy, time to staging scans, time to treatment commencement, due to its clear protocol and algorithms for staging and treatment; thus serving as an excellent surrogate for the effectiveness and timeliness of the different aspects of cancer care delivery.</p><p><strong>Materials and methods: </strong>In this retrospective study, we included all patients with newly diagnosed NPC from 1st January to 31st May from 2017 to 2020 at our centre. This time period was chosen as it coincided with the period in 2020 during the COVID-19 pandemic where there was the most strain on healthcare resources and the most restrictions on population movement within Singapore, which may impact on healthcare seeking behaviour. Narrowing down the time period to the first 5 months of the 4 respective years also allowed us to reduce the effect of annual seasonal variation in patient numbers seen as a result of holidays and festive periods such as the Lunar New Year and scheduled school holidays. Electronic medical records (EMR) were accessed. Only newly diagnosed NPC cases were included in our analysis. Patients with second synchronous primary malignancies or NPC disease recurrence were excluded. Data analysis was carried out using a combination of SPSS and Microsoft Excel.</p><p><strong>Results: </strong>Significantly, there was a reduction of 37-46.3% in newly diagnosed NPC cases during the peak of the COVID-19 pandemic from January to end May 2020 compared to the preceding three years. Despite the reduction in numbers of newly diagnosed NPC, there was no statistically significant differences in delay from biopsy to the first radiation oncology visit and from biopsy to the first day of treatment in 2020 compared to the preceding years. All the patients treated in our centre also received the standard NPC treatment for their disease stage as per international guidelines.</p><p><strong>Conclusion: </strong>We recommend a heightened awareness of the dangers of delaying cancer presentation and care in healthcare policies and resource allocation and at the same time, encourage patient's confidence in their ability to seek care. With the resurgence of new COVID-19 variants and case numbers worldwide and in Singapore, this study focuses upon the need to be aware of the exigencies of other clinical groups in resource utilization. It would be instructive to compare this stud","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":"2 1","pages":"17"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9909994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.1007/s44178-023-00042-z
Ning Kang, Si Zhang, Yuzhuo Wang
This commentary discusses a ground-breaking study on the use of personalized mRNA cancer vaccines for treating pancreatic ductal adenocarcinoma (PDAC), a highly malignant form of cancer. The study, which capitalizes on lipid nanoparticles for mRNA vaccine delivery, aims to induce an immune response against patient-specific neoantigens and offers a potential ray of hope for improving patient prognosis. Initial results from a Phase 1 clinical trial indicated a significant T cell response in half of the subjects, opening new avenues for PDAC treatment. However, despite the promising nature of these findings, the commentary emphasizes the challenges that remain. These include the complexity of identifying suitable antigens, the possibility of tumor immune escape, and the requirement for extensive large-scale trials to confirm long-term safety and efficacy. This commentary underscores the transformative potential of mRNA technology in oncology while highlighting the hurdles that need to be overcome for its widespread adoption.
{"title":"A personalized mRNA vaccine has exhibited potential in the treatment of pancreatic cancer.","authors":"Ning Kang, Si Zhang, Yuzhuo Wang","doi":"10.1007/s44178-023-00042-z","DOIUrl":"https://doi.org/10.1007/s44178-023-00042-z","url":null,"abstract":"<p><p>This commentary discusses a ground-breaking study on the use of personalized mRNA cancer vaccines for treating pancreatic ductal adenocarcinoma (PDAC), a highly malignant form of cancer. The study, which capitalizes on lipid nanoparticles for mRNA vaccine delivery, aims to induce an immune response against patient-specific neoantigens and offers a potential ray of hope for improving patient prognosis. Initial results from a Phase 1 clinical trial indicated a significant T cell response in half of the subjects, opening new avenues for PDAC treatment. However, despite the promising nature of these findings, the commentary emphasizes the challenges that remain. These include the complexity of identifying suitable antigens, the possibility of tumor immune escape, and the requirement for extensive large-scale trials to confirm long-term safety and efficacy. This commentary underscores the transformative potential of mRNA technology in oncology while highlighting the hurdles that need to be overcome for its widespread adoption.</p>","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":"2 1","pages":"18"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10028762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-01DOI: 10.1007/s44178-022-00019-4
Fengqi Zhou, Tianfu Yu, Fan Xiao, Binbin Wang, W. Tian, R. Xu, Xiaochun Zhao, Ailiang Zeng, Ning Liu, Yingyi Wang, Y. You, Junxia Zhang
{"title":"Periostin promotes EMT via inhibition of RIN1-mediated endocytosis of EGFR in gliomas","authors":"Fengqi Zhou, Tianfu Yu, Fan Xiao, Binbin Wang, W. Tian, R. Xu, Xiaochun Zhao, Ailiang Zeng, Ning Liu, Yingyi Wang, Y. You, Junxia Zhang","doi":"10.1007/s44178-022-00019-4","DOIUrl":"https://doi.org/10.1007/s44178-022-00019-4","url":null,"abstract":"","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47074885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号